1
|
Palezi SC, Fernandes SS, Martins VG. Oral disintegration films: applications and production methods. JOURNAL OF FOOD SCIENCE AND TECHNOLOGY 2023; 60:2539-2548. [PMID: 37599841 PMCID: PMC10439052 DOI: 10.1007/s13197-022-05589-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Revised: 08/17/2022] [Accepted: 08/28/2022] [Indexed: 08/22/2023]
Abstract
The use of orally disintegrating films (ODF) as a vehicle for the release of active compounds has drawn attention due to the advantages such as ease of swallowing, precise dosage, low thickness, flexibility, greater comfort and acceptability by the patient in relation to oral tablets, for do not require water for administration, it is ideal for people with difficulty in swallowing. In this review, recent advances in ODFs, their applications and production methods will be presented. The production of ODFs uses polymers, plasticizers and active compounds. Among the compounds added to the film that can affect its properties, the polymer used has a strong influence on the disintegration time and on the controlled release of active principles. Polymers used for the production of oral films must be non-toxic, have good wettability and spreadability, and may be of synthetic or natural origin. Regarding the methods used in the production of ODFs, those currently used are solvent evaporation and hot extrusion. However, one of the great challenges for the production of oral films is the scale up, from laboratory to industrial scale, as factors such as heating, mixing speed and temperatures can lead to changes in film quality. Recently, ODFs have been developed as carriers of natural compounds such as vitamins, phenolic compounds, antioxidant and antimicrobial activity. Thus, it was found that orally disintegrating films are an alternative for the release of active compounds, different from those already existing, which justifies the growing interest in this type of film.
Collapse
Affiliation(s)
- Simone Canabarro Palezi
- School of Chemistry and Food Engineering, Federal University of Rio Grande (FURG), Avenida Itália km 8, Carreiros, Rio Grande, RS 96203900 Brazil
| | - Sibele Santos Fernandes
- School of Chemistry and Food Engineering, Federal University of Rio Grande (FURG), Avenida Itália km 8, Carreiros, Rio Grande, RS 96203900 Brazil
| | - Vilásia Guimarães Martins
- School of Chemistry and Food Engineering, Federal University of Rio Grande (FURG), Avenida Itália km 8, Carreiros, Rio Grande, RS 96203900 Brazil
| |
Collapse
|
2
|
Palatable Levocetirizine Dihydrochloride Solid Dispersed Fast-Dissolving Films: Formulation and In Vitro and In Vivo Characterization. ScientificWorldJournal 2022; 2022:1552602. [PMID: 36479553 PMCID: PMC9722282 DOI: 10.1155/2022/1552602] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2022] [Revised: 09/11/2022] [Accepted: 09/14/2022] [Indexed: 11/30/2022] Open
Abstract
One of the most important issues for bitter-tasting drugs such as levocetirizine dihydrochloride (LCD) is the production of palatable dosage forms. LCD also has a delayed onset of action following oral administration. In this study, solid dispersed fast-dissolving films (FDFs) of LCD using the solvent casting method for oral application were prepared and evaluated. The FDF is composed of HPMC as the film forming polymer and different types of superdisintegrants (sodium starch glycolate, croscarmellose sodium, or crospovidone). FDF containing crospovidone showed the highest percentage release of the drug (100.54% ± 1.47 within 3 min.) and was chosen for fabricating into palatable solid dispersed FDFs using different ratios of gelatine. The results of Raman and FTIR revealed that the drug's crystalline structure has been disrupted, and the drug has intermolecular hydrogen bonds with gelatine. The solid dispersed FDF (LF-7), which contained the drug in the form of a 1 : 1 solid dispersion with gelatine, showed a rapid in vitro disintegration (25 seconds) and a burst release of the drug (99.22% ± 2.22 within one min). The in vivo studies were conducted on human participants and showed a significant (p < 0.05) reduction in disintegration time (9.43 ± 2.16 sec.) and higher taste masking ability of the solid dispersed FDF (LF-7) compared to the nonsolid dispersed FDF (LF-4). The stability studies indicated that the prepared FDF remained stable over three months. Overall, FDFs of levocetirizine dihydrochloride with a palatable and rapid onset of action were developed to relieve allergic symptoms.
Collapse
|
3
|
Pichayakorn W, Monton C, Sampaopan Y, Panrat K, Suksaeree J. Fabrication and Characterization of Buccal Film Loaded Self-emulsifying Drug Delivery System containing Lysiphyllum strychnifolium Stem Extracts. AAPS PharmSciTech 2022; 23:194. [PMID: 35821541 DOI: 10.1208/s12249-022-02341-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2022] [Accepted: 06/22/2022] [Indexed: 01/23/2023] Open
Abstract
Lysiphyllum strychnifolium has long been used as a popular herbal medicinal plant for treating fever and alcohol intoxication. This study aimed to prepare buccal film for L. strychnifolium stem extracts. These extracts were less soluble in water and were therefore loaded in self-emulsifying systems before being mixed into the film. Astilbin was selected as a chemical marker in L. strychnifolium stem extracts. Firstly, the L. strychnifolium stem extracts were entrapped in the self-emulsifying systems which were designed and optimized based on 32 factorial design. The optimal formulation was 0.60 g of surfactant-co-surfactant mixture (Tween® 80 and polyethylene glycol 400 in the ratio of 7.5:1) and 0.40 g of caprylic/capric triglyceride. Secondly, the optimal self-emulsifying system was loaded in the polymeric film which consisted of polyvinyl alcohol blended with poloxamer 407 using glycerin as a plasticizer. The properties of the prepared buccal film were unchanged, and the film showed an amorphous state, indicating all ingredients might be completely dissolved in the film. The buccal film could be placed in direct contact with the mouth without oral mucosal irritation, and showed a smooth and homogeneous surface with a rough and compact cross-sectional morphology. Astilbin content in the buccal film was 61.39 ± 11.45 µg/cm2. Astilbin was released from the buccal film while the permeation rate was low. The release mechanism was both swelling and diffusion, and followed anomalous or non-Fickian transfer. The permeability coefficient of the cumulative amount of astilbin permeated from buccal film was 1.0192 ± 0.1395 ×10-3 cm/h. Thus, the buccal film can be prepared by using a self-emulsifying system for herbal applications and shows potential as a safe and convenient form of oral drug administration.
Collapse
Affiliation(s)
- Wiwat Pichayakorn
- Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat-Yai, Songkhla, 90112, Thailand
| | - Chaowalit Monton
- Drug and Herbal Product Research and Development Center, College of Pharmacy, Rangsit University, Muang, Pathum Thani, 12000, Thailand
| | - Yupaporn Sampaopan
- Department of Pharmaceutical Chemistry, College of Pharmacy, Rangsit University, Muang, Pathum Thani, 12000, Thailand.,College of Oriental Medicine, Rangsit University, Muang, Pathum Thani, 12000, Thailand
| | - Kamon Panrat
- Pharmaceutical Laboratory Service Center, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat-Yai, Songkhla, 90112, Thailand
| | - Jirapornchai Suksaeree
- Department of Pharmaceutical Chemistry, College of Pharmacy, Rangsit University, Muang, Pathum Thani, 12000, Thailand.
| |
Collapse
|
4
|
Javed S, Hussain A, Shah PA, Raza SA, Anwer UU, Shamim R, Rasool F, Hafiz MA, Bukhari NI. Development of Optimized Sumatriptan-Prochlorperazine Combined Orodispersible Films Without Disintegrant: in vitro, ex vivo and in vivo Characterization. AAPS PharmSciTech 2022; 23:156. [PMID: 35655105 DOI: 10.1208/s12249-022-02307-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2022] [Accepted: 05/15/2022] [Indexed: 11/30/2022] Open
Abstract
Sumatriptan succinate and prochlorperazine maleate are a clinically proven combination for treating migraine and associated nausea and vomiting. Classical oral dosage forms are not frequently workable in migraine because of the associated nausea/vomiting, and no effective fixed dose combination is available. Thus, the aim of the study was to optimize a combined sumatriptan-prochlorperazine orodispersible film for rapid release of drugs. Orodispersible films were prepared by solvent casting method using varied amounts of polyvinyl alcohol and glycerol as film former and plasticizer, respectively, along with fixed levels of other ingredients employing central composite design. The optimum film (VF) demonstrated disintegration and total dispersion times as 21 s and 2.3 min, respectively. Tensile strength and Young's modulus were 8.86 ± 0.37 MPa and 24.15 ± 0.07 MPa, respectively. The in vitro T80% of both drugs from the ODF was achieved within 4 min. The film was palatable and disintegrated in 2 min in buccal cavity of human volunteers. Permeation study through goat mucosa demonstrated 100% permeation of both drugs within 15 min. X-Ray diffraction and differential scanning calorimetry supported drugs being amorphous and Fourier transform infrared demonstrated drug-excipient compatibility in optimized film. A judicious combination of sumatriptan succinate and prochlorperazine maleate could be prepared in orodispersible films for the possible relief of migraine.
Collapse
|
5
|
Rani KC, Parfati N, Aryani NLD, Winantari AN, Fitriani EW, Pradana AT, Nawatila R, Putranti AR, Irine F, Angelica F, Yohanes C, Avanti C. Development, Evaluation, and Molecular Docking of Oral Dissolving Film of Atenolol. Pharmaceutics 2021; 13:pharmaceutics13101727. [PMID: 34684021 PMCID: PMC8537485 DOI: 10.3390/pharmaceutics13101727] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2021] [Revised: 10/10/2021] [Accepted: 10/14/2021] [Indexed: 11/25/2022] Open
Abstract
The development of oral dissolving film (ODF) of atenolol is an attempt to enhance convenience and compliance for geriatric patients suffering from hypertension. Film former is the most essential component in ODF that determines the physical characteristic and drug release. In this study, three different types of film former including HPMC E5 4% (w/v), 5% (w/v), CMC-Na 3% (w/v), 4% (w/v), and Na-alginate 2.5% (w/v), 3% (w/v) were optimized in Formula 1 (F1) to Formula 6 (F6), respectively. A solvent casting method was employed to develop ODF of atenolol. The films formed by HPMC E5 produced a smooth and flexible surface, whereas CMC-Na and Na-alginate produced gritty textured films. Satisfactory results were obtained from several physical parameters such as film thickness, folding endurance, swelling index, and disintegration time. The homogeneity, drug content, and dissolution properties of ODF with HPMC exhibited better characteristics than the other formulas. Formula 1 exhibited the highest drug release compared to the other ODFs. The molecular docking results showed that there was a hydrogen bonding between atenolol and film formers which was also supported by the FTIR spectrum. The findings of this study suggest that HPMC E5 is the most favorable film former for ODF of atenolol.
Collapse
Affiliation(s)
- Karina Citra Rani
- Department of Pharmaceutics, Faculty of Pharmacy, University of Surabaya, Surabaya 60293, Indonesia; (K.C.R.); (N.P.); (N.L.D.A.); (A.N.W.); (E.W.F.); (A.T.P.); (R.N.); (A.R.P.); (F.I.); (F.A.); (C.Y.)
| | - Nani Parfati
- Department of Pharmaceutics, Faculty of Pharmacy, University of Surabaya, Surabaya 60293, Indonesia; (K.C.R.); (N.P.); (N.L.D.A.); (A.N.W.); (E.W.F.); (A.T.P.); (R.N.); (A.R.P.); (F.I.); (F.A.); (C.Y.)
| | - Ni Luh Dewi Aryani
- Department of Pharmaceutics, Faculty of Pharmacy, University of Surabaya, Surabaya 60293, Indonesia; (K.C.R.); (N.P.); (N.L.D.A.); (A.N.W.); (E.W.F.); (A.T.P.); (R.N.); (A.R.P.); (F.I.); (F.A.); (C.Y.)
| | - Agnes Nuniek Winantari
- Department of Pharmaceutics, Faculty of Pharmacy, University of Surabaya, Surabaya 60293, Indonesia; (K.C.R.); (N.P.); (N.L.D.A.); (A.N.W.); (E.W.F.); (A.T.P.); (R.N.); (A.R.P.); (F.I.); (F.A.); (C.Y.)
| | - Endang Wahyu Fitriani
- Department of Pharmaceutics, Faculty of Pharmacy, University of Surabaya, Surabaya 60293, Indonesia; (K.C.R.); (N.P.); (N.L.D.A.); (A.N.W.); (E.W.F.); (A.T.P.); (R.N.); (A.R.P.); (F.I.); (F.A.); (C.Y.)
| | - Aditya Trias Pradana
- Department of Pharmaceutics, Faculty of Pharmacy, University of Surabaya, Surabaya 60293, Indonesia; (K.C.R.); (N.P.); (N.L.D.A.); (A.N.W.); (E.W.F.); (A.T.P.); (R.N.); (A.R.P.); (F.I.); (F.A.); (C.Y.)
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand
| | - Roisah Nawatila
- Department of Pharmaceutics, Faculty of Pharmacy, University of Surabaya, Surabaya 60293, Indonesia; (K.C.R.); (N.P.); (N.L.D.A.); (A.N.W.); (E.W.F.); (A.T.P.); (R.N.); (A.R.P.); (F.I.); (F.A.); (C.Y.)
| | - Astridani Rizky Putranti
- Department of Pharmaceutics, Faculty of Pharmacy, University of Surabaya, Surabaya 60293, Indonesia; (K.C.R.); (N.P.); (N.L.D.A.); (A.N.W.); (E.W.F.); (A.T.P.); (R.N.); (A.R.P.); (F.I.); (F.A.); (C.Y.)
| | - Florencia Irine
- Department of Pharmaceutics, Faculty of Pharmacy, University of Surabaya, Surabaya 60293, Indonesia; (K.C.R.); (N.P.); (N.L.D.A.); (A.N.W.); (E.W.F.); (A.T.P.); (R.N.); (A.R.P.); (F.I.); (F.A.); (C.Y.)
| | - Florentia Angelica
- Department of Pharmaceutics, Faculty of Pharmacy, University of Surabaya, Surabaya 60293, Indonesia; (K.C.R.); (N.P.); (N.L.D.A.); (A.N.W.); (E.W.F.); (A.T.P.); (R.N.); (A.R.P.); (F.I.); (F.A.); (C.Y.)
| | - Cintya Yohanes
- Department of Pharmaceutics, Faculty of Pharmacy, University of Surabaya, Surabaya 60293, Indonesia; (K.C.R.); (N.P.); (N.L.D.A.); (A.N.W.); (E.W.F.); (A.T.P.); (R.N.); (A.R.P.); (F.I.); (F.A.); (C.Y.)
| | - Christina Avanti
- Department of Pharmaceutics, Faculty of Pharmacy, University of Surabaya, Surabaya 60293, Indonesia; (K.C.R.); (N.P.); (N.L.D.A.); (A.N.W.); (E.W.F.); (A.T.P.); (R.N.); (A.R.P.); (F.I.); (F.A.); (C.Y.)
- Correspondence: ; Tel.: +62-31-298-1000
| |
Collapse
|
6
|
Rambeau A, Cherifi F, Neviere Z, Licaj I, Clarisse B, Joly F. Platinum-induced nausea and vomiting in patients treated for head and neck cancer. Bull Cancer 2021; 108:449-454. [PMID: 33814187 DOI: 10.1016/j.bulcan.2021.01.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2020] [Revised: 12/10/2020] [Accepted: 01/02/2021] [Indexed: 11/25/2022]
Abstract
INTRODUCTION Swallowing difficulties in patients with advanced head and neck cancer (HNC) represent an obstacle to adequate antiemetic prophylaxis before chemotherapy. We aim to assess chemotherapy-induced nausea and vomiting (CINV) risk in HNC patients in our center, with a specific focus among patients who could not receive appropriate NK1 receptor antagonist (NK1-RA) prophylaxis. MATERIALS AND METHODS Prospective observational monocentric study. CINV were evaluated with the MASCC Antiemesis Tool self-questionnaire (MAT) for all patients treated by platinum-based chemotherapy for advanced HNC (January-April 2019), thereafter, only for patients without NK1-RA prophylaxis due to swallowing difficulties were included (May-October 2019). RESULTS Sixty-one patients were included (82% male, 49.2% reccurent/metastatic disease), 18 did not received NK1-RA prophylaxis due to swallowing difficulties. Among 52 patients included from January to April 2019, 17.3% reported swallowing difficulties. The chemotherapy regimen was highly and moderately emetic for 40 (65.6%) and 21 patients (34.4%), respectively. CINV was associated with both cisplatin-based chemotherapy (OR 10.66, 95% CI [2.17-52.08]) and exclusive chemotherapy (OR 7.76, 95% CI [1.79-33.78]). Patients who did not receive anti-NK1 prophylaxis had no more CINV than patients with adequate CINV prophylaxis. DISCUSSION CINV remains frequent in patients treated by platinum-based chemotherapy for HNC. Oral NK1-RA prophylaxis can be unavailable because of swallowing difficulties, without an increased risk of CINV.
Collapse
Affiliation(s)
- Audrey Rambeau
- Service d'oncologie médicale, centre François-Baclesse, 3, avenue du Général-Harris, 14000 Caen, France; Service de soins de support, centre François-Baclesse, avenue du Général-Harris, 14000 Caen, France.
| | - François Cherifi
- Service d'oncologie médicale, centre François-Baclesse, 3, avenue du Général-Harris, 14000 Caen, France
| | - Zoé Neviere
- Service d'oncologie médicale, centre François-Baclesse, 3, avenue du Général-Harris, 14000 Caen, France
| | - Idlir Licaj
- Service de recherche clinique, centre François-Baclesse, avenue du Général-Harris, 14000 Caen, France
| | - Bénédicte Clarisse
- Service de recherche clinique, centre François-Baclesse, avenue du Général-Harris, 14000 Caen, France
| | - Florence Joly
- Service d'oncologie médicale, centre François-Baclesse, 3, avenue du Général-Harris, 14000 Caen, France; Service de recherche clinique, centre François-Baclesse, avenue du Général-Harris, 14000 Caen, France
| |
Collapse
|
7
|
do Nascimento EG, de Azevedo EP, Alves-Silva MF, Aragão CFS, Fernandes-Pedrosa MF, da Silva-Junior AA. Supramolecular aggregates of cyclodextrins with co-solvent modulate drug dispersion and release behavior of poorly soluble corticosteroid from chitosan membranes. Carbohydr Polym 2020; 248:116724. [PMID: 32919548 DOI: 10.1016/j.carbpol.2020.116724] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2020] [Revised: 06/13/2020] [Accepted: 06/30/2020] [Indexed: 01/29/2023]
Abstract
In this study, the ability of different beta-cyclodextrins to facilitate homogeneous dispersion of triamcinolone acetonide (TA) into chitosan membranes is assessed. Drug loading was assessed through atomic force microscopy (AFM), scanning electron microscopy (MEV-FEG), and X-ray diffraction analyses. Drug interactions with the co-polymer were investigated with Fourier transform infrared spectroscopy, thermal analyses. Swelling assay, and in vitro drug release experiment were used to assess TA release behavior. Undispersed particles of drug were observed to remain in the simple chitosan membranes. Hydroxypropyl-β-cyclodextrin enabled the dispersion of TA into chitosan membranes and subsequent sustained drug release. In addition, the membrane performance as a drug delivery device is improved by adding specified amounts of the co-solvent triethanolamine. The experimental data presented in this study confirm the utility of our novel and alternative approach for obtaining a promising device for slow and controlled release of glucocorticoids, such as triamcinolone acetonide, for topical ulcerations.
Collapse
Affiliation(s)
- Ednaldo Gomes do Nascimento
- Laboratory of Pharmaceutical Technology and Biotechnology, Department of Pharmacy, Federal University of Rio Grande do Norte, UFRN, Gal. Gustavo Cordeiro de Farias, Petrópolis, 59072-570, Natal, RN, Brazil
| | - Eduardo Pereira de Azevedo
- Department of Pharmacy, Federal University of Potiguar, UnP, Av. Sen. Salgado Filho, 1610, Lagoa Nova, 59056-000, Natal, RN, Brazil
| | - Mariana Farias Alves-Silva
- Laboratory of Pharmaceutical Technology and Biotechnology, Department of Pharmacy, Federal University of Rio Grande do Norte, UFRN, Gal. Gustavo Cordeiro de Farias, Petrópolis, 59072-570, Natal, RN, Brazil
| | - Cícero Flávio S Aragão
- Laboratory of Quality Control of Pharmaceuticals, Department of Pharmacy, Federal University of Rio Grande do Norte, UFRN, Gal. Gustavo Cordeiro de Farias, Petrópolis, 59072-570, Natal, RN, Brazil
| | - Matheus F Fernandes-Pedrosa
- Laboratory of Pharmaceutical Technology and Biotechnology, Department of Pharmacy, Federal University of Rio Grande do Norte, UFRN, Gal. Gustavo Cordeiro de Farias, Petrópolis, 59072-570, Natal, RN, Brazil
| | - Arnóbio Antônio da Silva-Junior
- Laboratory of Pharmaceutical Technology and Biotechnology, Department of Pharmacy, Federal University of Rio Grande do Norte, UFRN, Gal. Gustavo Cordeiro de Farias, Petrópolis, 59072-570, Natal, RN, Brazil.
| |
Collapse
|
8
|
Laffleur F, Keckeis V. Advances in drug delivery systems: Work in progress still needed? Int J Pharm 2020; 590:119912. [DOI: 10.1016/j.ijpharm.2020.119912] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2020] [Revised: 06/03/2020] [Accepted: 06/10/2020] [Indexed: 02/07/2023]
|
9
|
Laffleur F, Keckeis V. Advances in drug delivery systems: Work in progress still needed? INTERNATIONAL JOURNAL OF PHARMACEUTICS-X 2020; 2:100050. [PMID: 32577616 PMCID: PMC7305387 DOI: 10.1016/j.ijpx.2020.100050] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/04/2020] [Revised: 06/03/2020] [Accepted: 06/10/2020] [Indexed: 01/10/2023]
Abstract
A new era of science and technology has emerged in pharmaceutical research with focus on developing novel drug delivery systems for oral administration. Conventional dosage forms like tablets and capsules are associated with a low bioavailability, frequent application, side effects and hence patient noncompliance. By developing novel strategies for drug delivery, researchers embraced an alternative to traditional drug delivery systems. Out of those, fast dissolving drug delivery systems are very eminent among pediatrics and geriatrics. Orally disintegrating films are superior over fast dissolving tablets as the latter are assigned with the risk of suffocation. Due to their ability of bypassing the dissolution and the first pass effect after oral administration, self-emulsifying formulations have also become increasingly popular in improving oral bioavailability of hydrophobic drugs. Osmotic devices enable a controlled drug delivery independent upon gastrointestinal conditions using osmosis as driving force. The advances in nanotechnology and the variety of possible materials and formulation factors enable a targeted delivery and triggered release. Vesicular systems can be easily modified as required and provide a controlled and sustained drug delivery to a specific site. This work provides an insight of the novel approaches in drug delivery covering the critical comparison between traditional and novel “advanced-designed” systems.
Collapse
Affiliation(s)
- Flavia Laffleur
- University of Innsbruck, Institute of Pharmacy, Department of Pharmaceutical Technology, Center for Molecular Biosciences Innsbruck, Innrain 80-82, 6020 Innsbruck, Austria
| | - Valérie Keckeis
- University of Innsbruck, Institute of Pharmacy, Department of Pharmaceutical Technology, Center for Molecular Biosciences Innsbruck, Innrain 80-82, 6020 Innsbruck, Austria
| |
Collapse
|
10
|
Ammanage A, Rodriques P, Kempwade A, Hiremath R. Formulation and evaluation of buccal films of piroxicam co-crystals. FUTURE JOURNAL OF PHARMACEUTICAL SCIENCES 2020. [DOI: 10.1186/s43094-020-00033-1] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
Abstract
Background
The aim of the present study was to enhance the solubility of piroxicam (BCS class II drug) using co-crystallization technique and formulate the buccal films of selected co-crystals for improved therapeutic utilization of drug. Co-crystals of drug with various co-formers (molar ratio 1:1) were prepared by solvent evaporation method and were screened for their aqueous solubility and percent drug content. The formation of co-crystals was confirmed by FTIR, DSC and XRD. Piroxicam co-crystals loaded buccal films were prepared and evaluated for in vitro drug release, ex vivo drug permeation while safety of formulation was determined by histopathological study.
Results
The co-crystals prepared with different co-formers have proved their potential to improve the solubility of the drug. Co-crystals of piroxicam-sucralose have shown six-folds more solubility than parent drug. FTIR analysis indicated shifting in characteristics peaks of piroxicam. DSC analysis showed an extra exothermic peak and alteration in characteristic endothermic peak. The powder x-ray diffraction pattern exhibited changes in 2θ values of intense peaks. Thus, formation of co-crystal was confirmed. Physical characters of buccal films were found to be within limits. Formulation F6 showed highest mucoadhesive strength (5617 ± 636 dynes /cm2) while formulation F2 showed highest in vitro drug release after 8 h, i.e., 94.557%. The ex vivo drug permeation of F2 was found to be 84.74%. The hisopathological study revealed that there was no damage to buccal mucosal tissue and was found to be intact.
Conclusion
The piroxicam-suralose co-crystals based mucoadhesive films of piroxicam could be a better formulation approach with improved solubility, safety, and therapeutic efficacy as compared to conventional tablets.
Graphical abstract
Collapse
|
11
|
Aldawsari HM, Badr-Eldin SM. Enhanced pharmacokinetic performance of dapoxetine hydrochloride via the formulation of instantly-dissolving buccal films with acidic pH modifier and hydrophilic cyclodextrin: Factorial analysis, in vitro and in vivo assessment. J Adv Res 2020; 24:281-290. [PMID: 32419956 PMCID: PMC7215178 DOI: 10.1016/j.jare.2020.04.019] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2020] [Revised: 04/19/2020] [Accepted: 04/27/2020] [Indexed: 01/03/2023] Open
Abstract
Instantly dissolving buccal films have gained attention owing to their easy administration and capability to surmount the hepatic first pass effect of drugs. Dapoxetine hydrochloride (DPX) has a low oral bioavailability due to significant hepatic first pass metabolism. In addition, DPX is a weakly basic drug with a pH dependent solubility that could limit its dissolution in the body neutral fluids. In order to surpass these challenges, this work aimed at enhancing DPX bioavailability via the formulation of instantly dissolving buccal films comprising a pH modifier and a hydrophilic cyclodextrin. Tartaric acid and hydroxypropyl beta-cyclodextrin were selected as dual solubilizing agents based on the screening study. 32 factorial design was employed for the formulation and optimization of DPX films. Statistical analysis revealed that hydroxypropyl methyl cellulose E5: maltodextrin ratio and propylene glycol concentrations have significant effects on mechanical properties, percent DPX dissolved after 5 min, and in vivo mouth dissolving time at P < 0.05. The optimized film [HPMC E5: MDX, 1:1 and 1% PG] showed no significant change of properties or drug dissolution upon storage at 40 °C/75% RH for a period of 3 months. In addition, the optimized film showed significantly enhanced absorption relative to the oral reference tablet. Therefore, the optimized film could be considered a promising delivery system for DPX with expected improved patient compliance and enhanced pharmacokinetic performance.
Collapse
Affiliation(s)
- Hibah M Aldawsari
- Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Shaimaa M Badr-Eldin
- Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.,Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt
| |
Collapse
|
12
|
Lim SY, Dafydd M, Ong J, Ord-McDermott LA, Board-Davies E, Sands K, Williams D, Sloan AJ, Heard CM. Mucoadhesive thin films for the simultaneous delivery of microbicide and anti-inflammatory drugs in the treatment of periodontal diseases. Int J Pharm 2020; 573:118860. [DOI: 10.1016/j.ijpharm.2019.118860] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2019] [Revised: 11/04/2019] [Accepted: 11/06/2019] [Indexed: 12/19/2022]
|
13
|
Evaluation of Dissolution Enhancement of Aprepitant Drug in Ternary Pharmaceutical Solid Dispersions with Soluplus® and Poloxamer 188 Prepared by Melt Mixing. SCI 2019. [DOI: 10.3390/sci1020048] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
In the present study Aprepitant (APT) ternary solid dispersions (SDs) were developed and evaluated for the first time. Specifically, ternary SDs of APT with Poloxamer 188 and Soluplus® (SOL) were prepared via melt mixing and compared to binary APT/Poloxamer 188 and APT/SOL SDs. Initially, combined thermo-gravimetric and hot-stage polarized light microscopy studies indicated that all tested compounds were thermally stable up to 280 °C, while Poloxamer 188 acted as a plasticizer to SOL by significantly reducing the temperature required to fully solubilize the API during SD preparation. Differential scanning calorimetry combined with wide angle X-ray diffraction studies showed that crystalline API was dispersed in both binary and ternary SDs, while Fourier transformation-infrared spectroscopy studies revealed no molecular interactions among the components. Scanning electron microscopy combined with EDAX element analysis showed that the API was dispersed in nano-scale within the polymer matrices, while increasing APT content led to increasing API nano-crystals within the SDs. Finally, dissolution studies showed that the prepared formulations enhanced dissolution of Aprepitant and its mechanism analysis was further studied. A mathematical model was also investigated to evaluate the drug release mechanism.
Collapse
|
14
|
Aprepitant Drug in Ternary Pharmaceutical Solid Dispersions with Soluplus® and Poloxamer 188 Prepared by Melt Mixing. SCI 2019. [DOI: 10.3390/sci1010029] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
In the present study Aprepitant (APT) ternary solid dispersions (SDs) were developed and evaluated for the first time. Specifically, ternary SDs of APT with Poloxamer 188 and Soluplus® (SOL) were prepared via melt mixing and compared to binary APT/Poloxamer 188 and APT/SOL SDs. Initially, combined thermo-gravimetric and hot-stage polarized light microscopy studies indicated that all tested compounds were thermally stable up to 280 °C, while Poloxamer 188 acted as a plasticizer to SOL by significantly reducing the temperature required to fully solubilize the API during SD preparation. Differential scanning calorimetry combined with wide angle X-ray diffraction studies showed that crystalline API was dispersed in both binary and ternary SDs, while Fourier transformation-infrared spectroscopy studies revealed no molecular interactions among the components. Scanning electron microscopy combined with EDAX element analysis showed that the API was dispersed in nano-scale within the polymer matrices, while increasing APT content led to increasing API nano-crystals within the SDs. Finally, dissolution studies showed that the prepared formulations enhanced dissolution of Aprepitant and its mechanism analysis was further studied. A mathematical model was also investigated to evaluate the drug release mechanism
Collapse
|